EcoDrugPlus

Proteasome Subunit Beta 11

Ensembl ID : ENSDCDG00000001923
Gene Symbol: PSMB11
1 Cross references
170 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSDCDG00000025825
Gene Symbol: LOC114770388
3 Cross references
221 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSDCDG00000018338
Gene Symbol: LOC114771701
3 Cross references
221 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSDCDG00000001928
Gene Symbol: LOC114788370
3 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSDCDG00000019417
Gene Symbol: LOC114790425
3 Cross references
221 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSDCDG00000019992
Gene Symbol: LOC114770234
3 Cross references
172 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSDCDG00000011353
Gene Symbol: LOC114774172
3 Cross references
220 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSDCDG00000011389
Gene Symbol: LOC114774169
3 Cross references
220 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSDCDG00000014553
Gene Symbol: LOC114770685
3 Cross references
211 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSDCDG00000001892
Gene Symbol: PRMT5
3 Cross references
199 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSDCDG00000024156
Gene Symbol: LOC114803328
3 Cross references
204 Possible Orthologues:

Protein Kinase C Alpha Type

Ensembl ID : ENSDCDG00000033838
Gene Symbol: LOC114785244
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).